

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**NINTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM JUNE 1, 2020 THROUGH JUNE 30, 2020**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	June 1, 2020 through June 30, 2020
Monthly Fees Incurred:	\$374,753.00

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$96.90

Total Fees and Expenses Due: \$374,849.90

This is a: X monthly _____ interim _____ final application

PRIOR APPLICATIONS:

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$492,071.20	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$449,490.80	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$342,642.40	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/30/2020	\$303,367.00	\$4,325.26	\$242,693.60	\$4,325.26

Note: The fee examiner's agreed upon \$30,000 reduction was allocated evenly across fees from the first interim period.

This statement (the "**Fee Statement**") of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, "**FTI**") as financial advisor to the Ad Hoc

Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from June 1, 2020 through and including June 30, 2020 (the “**Ninth Fee Period**”) amount to:

Professional Fees	\$374,753.00
Expenses	<u>96.90</u>
TOTAL	<u>\$374,849.90</u>

2. In accordance with the Orders, FTI has separately recorded its fees in connection with or relating to the allocation of value among the Debtors’ creditors (the “**Allocation Fees**”) and has not, to the best of its knowledge, included Allocation Fees in this Fee Statement. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$299,802.40
Expenses at 100%	<u>96.90</u>
TOTAL	<u>\$299,899.30</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Ninth Fee Period are set forth on the schedule annexed hereto as **Exhibit “A.”**

4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Ninth Fee Period is set forth on the schedule annexed hereto as **Exhibit “B.”**
5. Detailed time entry by task code during the Ninth Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. A summary of expenses incurred during the Ninth Fee Period is set forth on the schedule annexed hereto as **Exhibit “D.”**
7. Detailed breakdown of the expenses incurred during the Ninth Fee Period is set forth on the schedule annexed hereto as **Exhibit “E.”**
8. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Ninth Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

9. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than August **XX**, 2020 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “**Objection**”).
10. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
11. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be

preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
August XX, 2020

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY PROFESSIONAL
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020**

Professional	Position	Specialty	Billing Rate¹	Total Hours	Total Fees
Diaz, Matthew	Senior Managing Director	Restructuring	\$ 1,085	66.7	\$ 72,369.50
Greenblatt, Matthew	Senior Managing Director	Forensics	985	19.0	18,715.00
Joffe, Steven	Senior Managing Director	Tax	1,125	9.3	10,462.50
Simms, Steven	Senior Managing Director	Restructuring	1,295	2.4	3,108.00
Kyviakidis, Peter	Managing Director	Forensics	755	26.1	19,702.00
Suric, Emil	Senior Director	Healthcare	820	2.5	2,050.00
Costaldo, Nicole	Senior Director	Forensics	700	13.6	9,520.00
Bromberg, Brian	Director	Restructuring	815	185.6	151,264.00
Kim, Ye Darm	Senior Consultant	Restructuring	560	90.9	50,904.00
Tirabassi, Kathryn	Senior Consultant	Restructuring	560	0.6	336.00
Mazzari, Meredith	Senior Consultant	Forensics	530	21.6	11,448.00
Kurtz, Emma	Consultant	Restructuring	415	59.6	24,734.00
Hellmund-Mora, Marili	Associate	Restructuring	280	0.5	140.00
GRAND TOTAL				498.4	\$ 374,753.00

1. Reflects blended hourly rates. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT B

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY TASK
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	10.2	\$ 5,851.00
2	Cash & Liquidity Analysis	1.0	875.00
7	Analysis of Domestic Business Plan	46.9	36,863.00
8	Valuation and Related Matters	4.0	4,340.00
10	Analysis of Tax Issues	9.9	10,183.50
11	Prepare for and Attend Court Hearings	2.5	1,400.00
13	Analysis of Other Miscellaneous Motions	0.6	336.00
16	Analysis, Negotiate and Form of POR & DS	81.7	69,662.00
18	Review of Historical Transactions	117.7	87,547.00
19	Case Management	8.9	7,211.50
21	General Meetings with Counsel and/or Ad Hoc Committee	16.9	14,939.00
22	Meetings with Other Parties	3.4	2,954.00
24	Preparation of Fee Application	10.8	6,223.00
28	Review of IAC Business Plan	183.9	126,368.00
GRAND TOTAL¹		498.4	\$ 374,753.00

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
1	6/1/2020	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/2/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/3/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/4/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/5/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/9/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/10/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/11/2020	Diaz, Matthew	0.6	Review the Debtors' responses to the business plan/current results diligence questions.
1	6/11/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/12/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/15/2020	Diaz, Matthew	0.8	Review of the Debtors' YTD April 2020 financial report.
1	6/15/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/15/2020	Bromberg, Brian	1.0	Review of the Debtors' YTD April 2020 financial report.
1	6/16/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/17/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/17/2020	Bromberg, Brian	0.7	Prepare summary of the Debtors' performance re: March YTD financial report.
1	6/18/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/22/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/23/2020	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/24/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/25/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/26/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/29/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/30/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1 Total			10.2	
2	6/24/2020	Diaz, Matthew	0.6	Perform review of slides for presentation re: UCC call.
2	6/25/2020	Kim, Ye Darm	0.4	Review latest cash reporting update from Debtors.
2 Total			1.0	

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
7	6/1/2020	Bromberg, Brian	0.8	Discuss domestic business plan diligence process with team.
7	6/1/2020	Bromberg, Brian	0.7	Create topic list for business plan diligence discussion with team.
7	6/1/2020	Bromberg, Brian	1.3	Discuss business plan diligence process with counsel.
7	6/2/2020	Diaz, Matthew	1.0	Participate in a call with Dr. Brenkus to discuss the HRT motion.
7	6/2/2020	Bromberg, Brian	0.5	Discuss Domestic business plan with Houlihan team.
7	6/2/2020	Bromberg, Brian	2.1	Review domestic business plan report for presentation notes.
7	6/3/2020	Kim, Ye Darm	0.8	Process update to domestic business plan diligence deck re: product sales.
7	6/3/2020	Bromberg, Brian	0.9	Review and edit domestic business plan document.
7	6/3/2020	Bromberg, Brian	1.5	Participate in call with PJT Partners re: Purdue business plan diligence.
7	6/3/2020	Bromberg, Brian	1.5	Review the latest domestic business plan report.
7	6/3/2020	Bromberg, Brian	1.7	Prepare clarification document for domestic business plan diligence questions.
7	6/4/2020	Bromberg, Brian	1.2	Discuss Rhodes data requests with team and transmit to Debtor advisors.
7	6/9/2020	Kim, Ye Darm	0.1	Review buyer log for domestic business asset inbounds.
7	6/9/2020	Kim, Ye Darm	0.6	Prepare summary of call for internal distribution re: inbounds for domestic asset.
7	6/9/2020	Bromberg, Brian	0.5	Discuss outstanding diligence reports and presentations with team.
7	6/9/2020	Bromberg, Brian	0.7	Participate in call with Debtor advisors re: BuTrans and summarize for team.
7	6/9/2020	Bromberg, Brian	0.6	Participate in call with Dr. Brenkus re: OTC Naloxone and summarize for team.
7	6/9/2020	Kim, Ye Darm	0.5	Participate in call with Dr. Brenkus re: public health initiatives.
7	6/10/2020	Diaz, Matthew	1.1	Review the updated Purdue domestic business plan diligence report.
7	6/10/2020	Bromberg, Brian	0.5	Review domestic business plan report for presentation notes.
7	6/10/2020	Bromberg, Brian	0.6	Review latest version of domestic presentation.
7	6/11/2020	Kim, Ye Darm	0.8	Process revisions to US business plan diligence presentation.
7	6/11/2020	Kim, Ye Darm	0.9	Review Debtors' response to US business plan diligence question.
7	6/11/2020	Bromberg, Brian	0.6	Present to diligence committee on Domestic deck.
7	6/11/2020	Bromberg, Brian	0.9	Discuss domestic business plan presentations and information sharing issues with team.
7	6/11/2020	Bromberg, Brian	0.9	Organize domestic business plan presentations and create agenda for diligence committee call.
7	6/11/2020	Bromberg, Brian	0.8	Incorporate new dataroom information into presentation notes.
7	6/11/2020	Bromberg, Brian	0.9	Participate in coordination pre-call before diligence call.
7	6/11/2020	Bromberg, Brian	0.3	Discuss changes to domestic business plan presentation ahead of diligence meeting.
7	6/11/2020	Bromberg, Brian	1.1	Review answers provided in dataroom to domestic business plan diligence question.
7	6/12/2020	Kim, Ye Darm	1.0	Process revisions to US business plan presentation for Non-PEO information.
7	6/12/2020	Kim, Ye Darm	0.6	Continue processing revisions to US business plan presentation for non-PEO info.
7	6/12/2020	Bromberg, Brian	0.3	Research follow up NCSG questions re: domestic business plan.
7	6/12/2020	Bromberg, Brian	0.9	Participate in call with NCSG re: domestic business plan.
7	6/12/2020	Bromberg, Brian	2.4	Create non PEO version of domestic business plan deck.
7	6/12/2020	Bromberg, Brian	0.5	Discuss information sharing of PEO documents with team.
7	6/12/2020	Bromberg, Brian	1.0	Review non PEO version of domestic business plan deck.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
7	6/12/2020	Bromberg, Brian	0.8	Review documents provided in dataroom re: valuation considerations.
7	6/13/2020	Bromberg, Brian	0.5	Send outstanding NCSG questions and responses to internal team for review.
7	6/16/2020	Diaz, Matthew	1.1	Review the domestic business plan sensitivity cases.
7	6/16/2020	Kim, Ye Darm	0.6	Review responses to diligence questions re: HRT funding agreement.
7	6/16/2020	Kim, Ye Darm	1.7	Review Opioid-only financial models for domestic business plan.
7	6/16/2020	Bromberg, Brian	1.0	Review hypothetical scenario models provided by Debtors.
7	6/17/2020	Bromberg, Brian	1.0	Present re: Domestic business plan on Committee call.
7	6/17/2020	Bromberg, Brian	0.8	Participate in call with Houlihan team re: Committee call.
7	6/17/2020	Bromberg, Brian	0.5	Discuss Domestic business plan with Houlihan team.
7	6/17/2020	Bromberg, Brian	0.5	Prepare notes on presentations for Domestic business plan.
7	6/19/2020	Bromberg, Brian	0.3	Discuss analysis of generic products on domestic business plan.
7	6/25/2020	Kim, Ye Darm	1.4	Review production in dataroom to identify documents related to diligence requests.
7	6/29/2020	Diaz, Matthew	0.5	Participate on a call with the Debtors' re: Rhodes strategic initiatives.
7	6/29/2020	Diaz, Matthew	0.8	Review the Debtors' proposed strategic initiatives re: Rhodes.
7	6/29/2020	Kim, Ye Darm	1.1	Participate in meeting and review presentation re: Rhodes Prodrug.
7	6/29/2020	Bromberg, Brian	0.8	Participate in diligence call re: Rhodes with Debtors.
7	6/29/2020	Bromberg, Brian	0.4	Discuss public benefit structures with Houlihan.
7 Total			46.9	
8	6/18/2020	Diaz, Matthew	1.0	Review the Debtors' valuation analysis presentation.
8	6/22/2020	Diaz, Matthew	1.2	Participate in a call with the Committee and the Debtors' advisors to discuss PJT's valuation of the business.
8	6/22/2020	Diaz, Matthew	1.8	Review of the updated PJT valuation analysis.
8 Total			4.0	
10	6/4/2020	Joffe, Steven	0.5	Call with Brown Rudnick and Kramer regarding current tax matters.
10	6/4/2020	Joffe, Steven	0.5	Review prior rulings on qualified settlement funds.
10	6/4/2020	Bromberg, Brian	0.6	Participate in weekly tax call with Counsel.
10	6/11/2020	Joffe, Steven	0.4	Call with Brown Rudnick and Kramer regarding current tax matters.
10	6/11/2020	Bromberg, Brian	0.5	Participate in weekly tax call with Counsel.
10	6/12/2020	Joffe, Steven	0.6	Review KPMG presentation on tax considerations.
10	6/12/2020	Joffe, Steven	0.9	Participate on call with KPMG to review model.
10	6/12/2020	Bromberg, Brian	0.9	Participate in call with KPMG re: tax considerations.
10	6/13/2020	Diaz, Matthew	0.6	Review updated IAC tax analysis.
10	6/15/2020	Joffe, Steven	0.3	Review KPMG presentation on tax considerations.
10	6/17/2020	Joffe, Steven	1.2	Review proposed regulations regarding restitution.
10	6/18/2020	Joffe, Steven	0.6	Participate in call with Counsel re: tax considerations.
10	6/18/2020	Bromberg, Brian	0.5	Participate in weekly tax call with Counsel.
10	6/23/2020	Joffe, Steven	0.3	Review presentation to Creditors re: tax considerations.
10	6/24/2020	Joffe, Steven	0.3	Review recovery comparison presentation re: tax considerations.
10	6/29/2020	Joffe, Steven	0.7	Participate in call with Counsel re: tax considerations.
10	6/29/2020	Bromberg, Brian	0.5	Participate in weekly tax call with Counsel.
10 Total			9.9	
11	6/23/2020	Kim, Ye Darm	1.6	Participate telephonically in the Omnibus hearing.
11	6/23/2020	Kim, Ye Darm	0.9	Draft summary of omnibus hearing for distribution to internal team.
11 Total			2.5	
13	6/24/2020	Kim, Ye Darm	0.6	Review Counsel's summary re: omnibus hearing and UCC discovery stipulation.
13 Total			0.6	
16	6/1/2020	Kim, Ye Darm	0.6	Participate in diligence meeting with Counsel and HL re: 1B Report.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
16	6/8/2020	Kim, Ye Darm	0.6	Participate in internal meeting re: available distributable value.
16	6/8/2020	Bromberg, Brian	1.0	Discuss distributable value analysis with Houlihan.
16	6/8/2020	Bromberg, Brian	2.5	Prepare analysis re: distributable value over time.
16	6/8/2020	Bromberg, Brian	0.5	Discuss distributable value analysis with team.
16	6/8/2020	Bromberg, Brian	2.7	Edit distributable value analysis based based on internal discussions.
16	6/8/2020	Diaz, Matthew	1.0	Participate in a call with KL to discuss the recovery analysis.
16	6/8/2020	Diaz, Matthew	1.8	Develop and review draft distributable value analysis.
16	6/8/2020	Diaz, Matthew	0.8	Participate in a call with HL to discuss the distributable value analysis.
16	6/11/2020	Bromberg, Brian	0.8	Compile diligence questions on distributable value presentation.
16	6/11/2020	Diaz, Matthew	0.6	Review outline of Purdue waterfall analysis.
16	6/12/2020	Kim, Ye Darm	0.9	Review latest sale considerations presentation by PJT.
16	6/14/2020	Bromberg, Brian	1.0	Review questions on distributable value and send to Houlihan for discussion.
16	6/15/2020	Bromberg, Brian	0.9	Review latest distributable value analysis and prepare question list to Debtors' advisors.
16	6/15/2020	Diaz, Matthew	1.7	Review the updated PJT valuation presentation re: sale considerations.
16	6/15/2020	Diaz, Matthew	1.2	Review the updated waterfall analysis.
16	6/17/2020	Bromberg, Brian	1.2	Review latest draft of distributable value analysis.
16	6/17/2020	Diaz, Matthew	1.2	Review the waterfall analysis.
16	6/18/2020	Kim, Ye Darm	0.5	Participate in call re: illustrative distributable value.
16	6/18/2020	Bromberg, Brian	1.3	Edit distributable value presentation based on internal comments.
16	6/18/2020	Bromberg, Brian	0.8	Discuss distributable value presentation with counsel.
16	6/18/2020	Bromberg, Brian	1.5	Edit distributable value analysis based on conversations with team.
16	6/18/2020	Bromberg, Brian	2.2	Prepare additional slides re: distributable value presentation.
16	6/18/2020	Bromberg, Brian	0.3	Request Non-PEO version of information re: distributable value analysis.
16	6/18/2020	Bromberg, Brian	1.2	Process revisions to distributable value presentation.
16	6/18/2020	Bromberg, Brian	0.8	Edit distributable value presentation based on discussions with counsel.
16	6/18/2020	Diaz, Matthew	0.9	Review the presentation to the committee on the waterfall analysis.
16	6/18/2020	Diaz, Matthew	1.2	Review the updated waterfall analysis.
16	6/19/2020	Kim, Ye Darm	0.9	Review latest draft of illustrative distributable value analysis.
16	6/19/2020	Bromberg, Brian	1.5	Edit distributable value presentation based on internal comments.
16	6/19/2020	Bromberg, Brian	0.9	Continue to revise distributable value presentation based on internal comments.
16	6/19/2020	Diaz, Matthew	1.2	Review the updated waterfall analysis report to the AHC.
16	6/20/2020	Bromberg, Brian	0.5	Prepare responses to questions on distributable value analysis.
16	6/21/2020	Diaz, Matthew	1.5	Finalize the waterfall recovery analysis.
16	6/22/2020	Kim, Ye Darm	0.6	Process updates to comparison of nominal and sale value comparison analysis.
16	6/22/2020	Kim, Ye Darm	0.5	Participate in call re: illustrative distributable value.
16	6/22/2020	Kim, Ye Darm	1.8	Prepare comparison of nominal and sale values for distributable value analysis.
16	6/22/2020	Bromberg, Brian	0.5	Participate in discussion re: distributable value analysis with Houlihan.
16	6/22/2020	Bromberg, Brian	2.2	Process revisions to distributable value analysis presentation.
16	6/22/2020	Bromberg, Brian	0.8	Discuss tax considerations re: distributable value analysis.
16	6/22/2020	Bromberg, Brian	2.2	Revise distributable value analysis based on internal discussions.
16	6/22/2020	Bromberg, Brian	0.5	Participate in distributable value analysis with internal team.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
16	6/22/2020	Bromberg, Brian	2.3	Continue to revise distributable value analysis.
16	6/22/2020	Bromberg, Brian	1.0	Participate in meeting with Debtors re: valuation considerations.
16	6/22/2020	Bromberg, Brian	2.5	Process revisions to distributable value analysis for updates from Debtors' presentation.
16	6/22/2020	Bromberg, Brian	2.5	Discount valuation cash flows per distributable value analysis.
16	6/22/2020	Diaz, Matthew	1.6	Review the updated recovery analysis presentation.
16	6/22/2020	Kim, Ye Darm	1.1	Participate in call re: distributable value PJT analysis.
16	6/23/2020	Kim, Ye Darm	0.4	Review discounted PBC scenario analysis.
16	6/23/2020	Bromberg, Brian	1.9	Prepare revisions to value waterfall model.
16	6/23/2020	Bromberg, Brian	1.8	Revise presentation on total value based on conversation with internal team.
16	6/23/2020	Bromberg, Brian	0.8	Continue to revise presentation on total value based on conversation with team.
16	6/23/2020	Bromberg, Brian	1.0	Discuss distributable value with internal team.
16	6/23/2020	Bromberg, Brian	0.6	Participate in discussion re: distributable value with Houlihan.
16	6/23/2020	Bromberg, Brian	2.5	Review and revise distributable value presentation based on counsel's comments.
16	6/23/2020	Diaz, Matthew	2.4	Review the Debtors' presentation re: valuation analysis.
16	6/23/2020	Diaz, Matthew	2.5	Review the updated recovery analysis.
16	6/24/2020	Kim, Ye Darm	0.6	Participate in call re: illustrative distributable value.
16	6/24/2020	Bromberg, Brian	0.7	Participate in discussion re: distributable value with counsel.
16	6/24/2020	Bromberg, Brian	1.2	Finalize distributable value presentation draft for meeting with Committee.
16	6/24/2020	Bromberg, Brian	1.5	Participate in AHC call re: distributable value.
16	6/24/2020	Diaz, Matthew	1.2	Finalize the Purdue waterfall analysis for the report to the Committee.
16	6/25/2020	Bromberg, Brian	0.4	Discuss distributable value analysis with Debtor advisors.
16	6/30/2020	Kim, Ye Darm	2.2	Prepare shorter presentation for distributable value.
16	6/30/2020	Bromberg, Brian	0.7	Review condensed distributable value presentation.
16	6/30/2020	Bromberg, Brian	0.3	Discuss updates on distributable value analysis with internal team.
16	6/30/2020	Diaz, Matthew	0.7	Review presentation re: domestic business diligence to the tribal group.
16 Total			81.7	
18	6/1/2020	Kim, Ye Darm	0.6	Participate in internal pre-call meeting re: 1B report diligence meeting with KL and HL.
18	6/1/2020	Costaldo, Nicole	2.3	Conduct preliminary review of the inventory of documents provided to date re: non cash transfers of value report
18	6/1/2020	Kyviakidis, Peter	1.0	Participate on a call to discuss the detailed information requests and questions to be posed to AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/1/2020	Kyviakidis, Peter	0.5	Analyze the Intercompany and Non-Cash Transfer of Value Analysis.
18	6/1/2020	Kyviakidis, Peter	0.8	Read listing of information items provided by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/1/2020	Bromberg, Brian	1.8	Review Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/2/2020	Greenblatt, Matthew	0.8	Prepare and review detailed questions and document request list for AlixPartners based upon continued review of Cash Transfers Report
18	6/2/2020	Greenblatt, Matthew	1.2	Conduct initial review of the Non-Cash Transfers Report prepared by AlixPartners.
18	6/2/2020	Mazzari, Meredith	1.1	Participate in call re: document index for Intercompany and Non-Cash Transfers Of Value Analysis.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
18	6/2/2020	Mazzari, Meredith	0.4	Participate in call to debrief on AlixPartners inquiries re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/2/2020	Mazzari, Meredith	1.1	Document reconciliation procedures performed re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/2/2020	Kyviakidis, Peter	1.5	Analyze the Intercompany and Non-Cash Transfers of Value Analysis by AlixPartners.
18	6/3/2020	Costaldo, Nicole	2.4	Review the executive summary of the non-cash transfers report and prepare for internal call with team to continue to discuss the non-cash transfers report
18	6/3/2020	Mazzari, Meredith	0.7	Document completeness procedures performed by AlixPartners from Cash Transfers of Value Report
18	6/3/2020	Kyviakidis, Peter	2.9	Draft internal document on observations and questions for AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/3/2020	Kyviakidis, Peter	2.9	Analyze the Intercompany and Non-Cash transfers of value Analysis.
18	6/3/2020	Bromberg, Brian	1.7	Review 1B transfers report re: re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/3/2020	Bromberg, Brian	1.2	Participate in Ad Hoc Committee update call re: IACs and 1B report.
18	6/3/2020	Bromberg, Brian	1.2	Prepare presentation notes for ad hoc committee call on the 1B report.
18	6/4/2020	Costaldo, Nicole	0.9	Conference with team regarding additional diligence questions to review results of the non-cash transfers report.
18	6/4/2020	Diaz, Matthew	1.5	Review the Intercompany and Non-Cash Transfers Of Value Analysis report.
18	6/4/2020	Kim, Ye Darm	0.5	Participate in internal discussion re: 1B report.
18	6/4/2020	Kyviakidis, Peter	3.3	Draft internal document on observations and questions for AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/4/2020	Kyviakidis, Peter	3.5	Continue analysis of the Intercompany and Non-cash transfers of Value Analysis.
18	6/4/2020	Bromberg, Brian	2.3	Review Intercompany and Non-Cash Transfers Of Value Analysis..
18	6/4/2020	Kurtz, Emma	0.3	Discuss internally re: non-cash transfers report and related presentation.
18	6/5/2020	Kim, Ye Darm	1.2	Process updates to 1B report summary presentation.
18	6/5/2020	Kim, Ye Darm	2.7	Prepare summary presentation of 1B report.
18	6/5/2020	Kyviakidis, Peter	2.8	Continue analysis of the Intercompany and Non-Cash Transfers of Value Analysis.
18	6/7/2020	Bromberg, Brian	1.2	Review summary presentation on 1B report.
18	6/8/2020	Costaldo, Nicole	0.3	Conduct final review of questions and information requests to AlixPartners re: Cash and Non-Cash Transfers of Value Report
18	6/8/2020	Greenblatt, Matthew	1.8	Conduct review of the Non-Cash Transfers report and drafted document request and list of inquiries for AlixPartners team.
18	6/8/2020	Kim, Ye Darm	1.9	Prepare additional overview slides for presentation summarizing 1B Report.
18	6/8/2020	Bromberg, Brian	0.5	Review initial inquiries list to AlixPartners related to transfer reports.
18	6/8/2020	Bromberg, Brian	1.6	Provide comments on 1B report presentation and discuss with internal team.
18	6/9/2020	Greenblatt, Matthew	1.4	Prepare further analysis of AlixPartners' Non-Cash Transfers report and continued summary of preliminary thoughts and observations.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
18	6/9/2020	Mazzari, Meredith	1.6	Document assumptions made by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/9/2020	Mazzari, Meredith	1.7	Prepare review of completeness procedures performed by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/9/2020	Kim, Ye Darm	1.7	Process revisions to summary presentation re: 1B report.
18	6/9/2020	Bromberg, Brian	0.6	Finalize 1B report presentation slides for internal review.
18	6/9/2020	Bromberg, Brian	0.8	Review latest version of 1B report presentation slide.
18	6/9/2020	Bromberg, Brian	0.8	Review public version of 1B report filed in the docket.
18	6/10/2020	Costaldo, Nicole	1.2	Prepare for and correspond with accounting team re: call with AlixPartners to discuss the Cash and Non-Cash Transfers.
18	6/10/2020	Diaz, Matthew	1.8	Perform detailed review re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/10/2020	Diaz, Matthew	1.4	Review the draft presentation to the AHC re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/10/2020	Kim, Ye Darm	2.3	Prepare schedules of categories of transfers re: 1B Report.
18	6/10/2020	Kim, Ye Darm	1.6	Process updates and revisions to 1B Report presentation for the diligence subcommittee.
18	6/10/2020	Kyviakidis, Peter	0.5	Prepare diligence questions to AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/10/2020	Bromberg, Brian	0.7	Discuss transfer reports and diligence questions with internal team.
18	6/10/2020	Bromberg, Brian	1.5	Provide revisions to the latest version of non cash transfer presentation slides.
18	6/10/2020	Bromberg, Brian	1.6	Review non cash transfer presentation slides.
18	6/11/2020	Greenblatt, Matthew	0.8	Develop investigative procedures to identify additional potential insider payments to disclosed and undisclosed Sackler family members.
18	6/11/2020	Greenblatt, Matthew	0.4	Prepare summary of initial observations and inquiries for AlixPartners team for both the Cash Transfers and the Non-Cash Transfers reports.
18	6/11/2020	Mazzari, Meredith	0.8	Document assumptions made by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/11/2020	Kim, Ye Darm	1.1	Prepare schedule of variances by category re: 1B report.
18	6/11/2020	Kyviakidis, Peter	2.3	Review analyses re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/12/2020	Greenblatt, Matthew	0.8	Correspond AlixPartners and FTI teams regarding FTI's initial observations and inquiries for AlixPartners team for both the Cash Transfers and the Non-Cash Transfers reports.
18	6/15/2020	Greenblatt, Matthew	1.3	Continue review of AlixPartners' Non-Cash Transfers report and develop a detailed document request and question list for AlixPartners team.
18	6/15/2020	Mazzari, Meredith	1.1	Document reconciliation procedures performed by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/17/2020	Mazzari, Meredith	0.9	Document reconciliation procedures performed by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/17/2020	Mazzari, Meredith	0.5	Document assumptions made by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/17/2020	Mazzari, Meredith	0.5	Document completeness procedures performed by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/17/2020	Bromberg, Brian	0.5	Review questions on cash transfers report.
18	6/18/2020	Greenblatt, Matthew	1.2	Continue review of the Non-Cash Transfers report.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
18	6/18/2020	Mazzari, Meredith	1.7	Document assumptions made by AlixPartners in Intercompany & Non-Cash Transfers Analysis
18	6/18/2020	Mazzari, Meredith	0.5	Document reconciliation procedures performed by AlixPartners from Intercompany & Non-Cash Transfers Analysis
18	6/19/2020	Kyviakidis, Peter	1.8	Review internal analyses re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/23/2020	Costaldo, Nicole	1.8	Prepare for call with AlixPartners re: scope and procedures performed for the Cash Transfers of Value report.
18	6/23/2020	Greenblatt, Matthew	1.5	Continue review of AlixPartners' Non-Cash Transfers report and develop a detailed document request and question list for AlixPartners team.
18	6/24/2020	Costaldo, Nicole	1.7	Attend call with AlixPartners and prepare summary of discussion re: the Cash Transfers of Value Report.
18	6/24/2020	Greenblatt, Matthew	0.3	Prepare summary of preliminary observations from discussion with AlixPartners team and coordinate next steps with FTI team.
18	6/24/2020	Greenblatt, Matthew	2.3	Review the Cash Transfers Report and update draft outline of questions for discussion with AlixPartners.
18	6/24/2020	Greenblatt, Matthew	1.2	Participate in conference call with Alix and FTI teams regarding the Cash Transfers report.
18	6/24/2020	Mazzari, Meredith	0.2	Participate in internal discussion on work plan re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/24/2020	Kyviakidis, Peter	1.3	Participate on call with AlixPartners to discuss the nature and scope of AlixPartners's project work procedures performed re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/24/2020	Bromberg, Brian	0.8	Participate in call with AlixPartners re: cash transfers report.
18	6/25/2020	Greenblatt, Matthew	1.0	Participate in conference call with Alix and FTI teams regarding the Non-Cash Transfers report.
18	6/25/2020	Greenblatt, Matthew	1.5	Continue review of the Non-Cash Transfers Report and update FTI's draft outline of questions for discussion with AlixPartners' team.
18	6/25/2020	Greenblatt, Matthew	0.2	Coordinate next steps with FTI team following discussion with AlixPartners team regarding the Non-Cash Transfers Report.
18	6/25/2020	Mazzari, Meredith	3.0	Review and analyze Appendix B & D from Cash Transfers of Value Analysis, Appendix 1 from Intercompany and Non-Cash Transfers of Value Analysis.
18	6/25/2020	Mazzari, Meredith	0.6	Participate in internal discussion on analyses re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/25/2020	Mazzari, Meredith	0.3	Continue to review and analyze Appendix B & D from Cash Transfers of Value Analysis, Appendix 1 from Intercompany and Non-Cash Transfers of Value Analysis.
18	6/25/2020	Mazzari, Meredith	1.1	Participate in discussion with AlixPartners re: re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/25/2020	Kyviakidis, Peter	1.0	Participate on call with AlixPartners in order to discuss the nature and scope of AlixPartners's project work procedures re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/29/2020	Greenblatt, Matthew	1.3	Summarize observations from both Cash and Non-Cash Transfers of Value reports by Alix Partners.
18	6/29/2020	Costaldo, Nicole	3.0	Conference with team to discuss work plan and deck re: opinion on the coverage of Alix Partners analyses.
18	6/29/2020	Mazzari, Meredith	0.3	Quality check review of slide deck summarizing call with AlixPartners and proposed analyses.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
18	6/29/2020	Mazzari, Meredith	2.2	Document and review files provided by AlixPartners in connection with Cash Transfers of Value Analysis.
18	6/29/2020	Mazzari, Meredith	1.3	Review and analyze Appendix B & D from Cash Transfers of Value Analysis, Appendix 1 from Intercompany and Non-Cash Transfers of Value Analysis/
18 Total			117.7	
19	6/1/2020	Simms, Steven	0.4	Participate in internal correspondence on outstanding workstreams.
19	6/3/2020	Simms, Steven	0.4	Participate in internal correspondence on outstanding workstreams.
19	6/9/2020	Simms, Steven	0.4	Participate in internal correspondence on outstanding workstreams.
19	6/12/2020	Simms, Steven	0.4	Participate in internal correspondence on outstanding workstreams.
19	6/15/2020	Kurtz, Emma	0.6	Update dataroom index to incorporate recently uploaded documents to share with team.
19	6/16/2020	Kim, Ye Darm	1.2	Prepare historical AHC professional fee tracker to forecast run rate for committee.
19	6/16/2020	Bromberg, Brian	0.8	Review historical AHC professional fee tracker to forecast run rate for committee.
19	6/16/2020	Bromberg, Brian	0.8	Process revisions to historical AHC professional fee tracker to forecast run rate for committee.
19	6/17/2020	Kim, Ye Darm	0.6	Update the historical AHC professional fee tracker per Counsel's comments to forecast run rate for committee.
19	6/17/2020	Bromberg, Brian	0.9	Coordinate with Counsel on assumptions re: historical AHC professional fee tracker to forecast run rate for committee.
19	6/18/2020	Kim, Ye Darm	0.4	Review historical allocation related time re: historical AHC professional fee tracker to forecast run rate for committee.
19	6/18/2020	Kim, Ye Darm	0.6	Update the historical AHC professional fee tracker per Counsel's comments to forecast run rate for committee.
19	6/26/2020	Simms, Steven	0.4	Participate in internal correspondence on outstanding workstreams.
19	6/29/2020	Kurtz, Emma	0.6	Update the dataroom index to include recently uploaded documents to share with team.
19	6/30/2020	Simms, Steven	0.4	Participate in internal correspondence on outstanding workstreams.
19 Total			8.9	
21	6/1/2020	Diaz, Matthew	0.5	Participate in a call with Kramer to discuss open due diligence items.
21	6/3/2020	Diaz, Matthew	1.2	Participate in the hearing with the AHC to discuss the non cash report and other topics.
21	6/11/2020	Diaz, Matthew	1.1	Participate in a call with the diligence subcommittee to discuss IAC, Purdue USA and non cash transfer due diligence.
21	6/11/2020	Diaz, Matthew	0.5	Participate in call with counsel and Houlihan to prepare for the due diligence sub committee meeting.
21	6/11/2020	Kim, Ye Darm	1.0	Participate in call with diligence subcommittee re: IAC, domestic business plan, 1B report updates.
21	6/11/2020	Kim, Ye Darm	0.6	Participate in internal prep call before diligence subcommittee call.
21	6/11/2020	Kim, Ye Darm	0.5	Participate in pre-call with KL and HL for diligence subcommittee call.
21	6/17/2020	Diaz, Matthew	1.0	Participate in a meeting with the AHC to discuss business due diligence, the bar date and other topics.
21	6/17/2020	Diaz, Matthew	0.7	Review materials to prepare for the call with the Committee.
21	6/17/2020	Kim, Ye Darm	1.1	Participate in meeting with AHC re: diligence updates.
21	6/22/2020	Kim, Ye Darm	0.5	Participate in follow up call re: diligence subcommittee call.
21	6/24/2020	Joffe, Steven	1.2	Participate in weekly AHC committee call re: tax considerations.
21	6/24/2020	Diaz, Matthew	1.5	Participate on a call with the AHC to discuss the waterfall analysis.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
21	6/24/2020	Diaz, Matthew	0.7	Review materials to prepare for the call with the Committee.
21	6/24/2020	Kim, Ye Darm	1.1	Participate in weekly AHC meeting re: illustrative cash value.
21	6/30/2020	Joffe, Steven	1.8	Participate in weekly AHC committee call re: tax considerations.
21	6/30/2020	Kim, Ye Darm	1.9	Participate in call with AHC re: bankruptcy strategies.
21 Total			16.9	
22	6/12/2020	Diaz, Matthew	1.4	Participate in a call with the NCSG re: the non cash transfers report, the IAC business plan and the domestic business plan.
22	6/12/2020	Diaz, Matthew	0.6	Review materials to prepare for the call with the NCSG.
22	6/12/2020	Kim, Ye Darm	1.4	Participate in meeting with NCSG re: IAC, US business plan, 1B report updates.
22 Total			3.4	
24	6/9/2020	Tirabassi, Kathryn	0.2	Prepare updated billing summary.
24	6/10/2020	Tirabassi, Kathryn	0.4	Finalize April 2020 Fee Statement.
24	6/11/2020	Hellmund-Mora, Marili	0.5	Finalize the April fee application.
24	6/16/2020	Kim, Ye Darm	2.7	Prepare May Fee application.
24	6/16/2020	Kim, Ye Darm	1.1	Continue preparation of May fee application.
24	6/16/2020	Kim, Ye Darm	2.6	Continue preparation of May fee application.
24	6/17/2020	Diaz, Matthew	0.6	Review the May fee statement.
24	6/18/2020	Kim, Ye Darm	1.8	Process revisions to May fee application.
24	6/26/2020	Kim, Ye Darm	0.9	Review and finalize May fee app for distribution to Counsel.
24 Total			10.8	
28	6/1/2020	Diaz, Matthew	0.5	Review outstanding diligence items re: IACs.
28	6/1/2020	Kurtz, Emma	0.5	Participate in internal discussion re: IAC diligence progress and cash transfer report.
28	6/1/2020	Bromberg, Brian	1.1	Review and process revisions to IAC diligence report for the AHC.
28	6/1/2020	Bromberg, Brian	1.0	Review IAC diligence report to prepare notes for presentation.
28	6/2/2020	Diaz, Matthew	0.5	Review the discovery disputes letter between the UCC and the IACs.
28	6/2/2020	Bromberg, Brian	0.7	Review updated IAC diligence questions list.
28	6/2/2020	Bromberg, Brian	0.8	Review UCC letter re: IACs and diligence issues.
28	6/2/2020	Bromberg, Brian	1.0	Review newly provided dataroom documents re: IAC diligence.
28	6/3/2020	Diaz, Matthew	1.7	Review the updated IAC due diligence responses and outstanding questions.
28	6/3/2020	Kurtz, Emma	1.2	Prepare draft question list for call with IACs CFO.
28	6/3/2020	Bromberg, Brian	1.2	Review IAC diligence report for presentation notes.
28	6/4/2020	Diaz, Matthew	1.1	Continue review of the IAC diligence responses and outstanding questions list.
28	6/4/2020	Kurtz, Emma	0.5	Prepare revisions to proposed question list for call with IAC CFO.
28	6/4/2020	Bromberg, Brian	0.5	Review product liability claims for IAC partner.
28	6/4/2020	Bromberg, Brian	2.5	Prepare topics list for call with IAC CFO.
28	6/4/2020	Bromberg, Brian	1.3	Finalize agenda for diligence discussion and questions list re: IAC CFO call.
28	6/5/2020	Diaz, Matthew	0.9	Perform detailed review of the question list for the call with IAC CFO.
28	6/5/2020	Diaz, Matthew	0.6	Participate in call to discuss IAC due diligence status.
28	6/5/2020	Kurtz, Emma	0.3	Discuss internally re: next steps in IAC diligence process.
28	6/5/2020	Kurtz, Emma	2.6	Prepare detailed variance analysis of November plan to Revised plan by individual entity to evaluate changes to both historical results and projections.
28	6/5/2020	Kurtz, Emma	0.3	Prepare updated diligence request list to incorporate additional clarifying questions re: IACs financial performance.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
28	6/5/2020	Bromberg, Brian	0.9	Finalize diligence question list to send to IACs re: IAC CFO call.
28	6/5/2020	Bromberg, Brian	2.8	Review IAC projection variance files.
28	6/5/2020	Bromberg, Brian	0.8	Discuss IAC diligence status with Debtor and UCC advisors.
28	6/5/2020	Bromberg, Brian	2.4	Review latest IAC financial information provided.
28	6/5/2020	Bromberg, Brian	0.5	Discuss changes to make to analysis re: IAC diligence.
28	6/5/2020	Bromberg, Brian	1.2	Finalize agenda and questions list after discussion with team re: IAC CFO call.
28	6/7/2020	Diaz, Matthew	0.5	Review the UCC letter and due diligence request list being sent to IAC CFO.
28	6/8/2020	Suric, Emil	0.5	Prepare follow up diligence information request re: product forecasts.
28	6/8/2020	Kurtz, Emma	1.3	Prepare analysis of net marketing support payments adjustment to the revised budget.
28	6/8/2020	Bromberg, Brian	0.9	Finalize CFO question list to send to IACs.
28	6/8/2020	Bromberg, Brian	1.0	Review updated analysis on P&L variance and marketing support payments re: IAC diligence.
28	6/9/2020	Suric, Emil	0.5	Participate in Purdue diligence call re: product forecasts.
28	6/9/2020	Kurtz, Emma	0.4	Discuss internally re: analysis of revised business plan and preparation of revised presentation.
28	6/9/2020	Kurtz, Emma	1.3	Prepare revised business plan analysis presentation to incorporate the revised business plan.
28	6/9/2020	Kurtz, Emma	2.8	Prepare analysis of updated price/volume information to evaluate sales by product for the revised business plan.
28	6/9/2020	Bromberg, Brian	1.5	Review updated IAC P&L files.
28	6/9/2020	Bromberg, Brian	0.5	Provide list of IAC documents relied upon re: IAC diligence presentation.
28	6/9/2020	Bromberg, Brian	0.4	Discuss IAC business plan diligence with internal team.
28	6/9/2020	Bromberg, Brian	0.5	Discuss IAC diligence work plan with internal team.
28	6/9/2020	Bromberg, Brian	1.3	Review prior version of IAC presentation for additional updates.
28	6/10/2020	Diaz, Matthew	1.1	Review the updated IAC diligence report.
28	6/10/2020	Kim, Ye Darm	0.5	Participate in discussion re: revisions to IAC presentation.
28	6/10/2020	Kurtz, Emma	2.2	Prepare updated analysis of sales by product by country and region to evaluate revised business plan projections.
28	6/10/2020	Kurtz, Emma	2.6	Prepare revised business plan overview slides re: IAC revised business plan presentation.
28	6/10/2020	Kurtz, Emma	0.3	Discuss internally re: work plan to prepare revised IAC business plan analysis presentation.
28	6/10/2020	Bromberg, Brian	0.3	Review response from IAC management re: diligence question list.
28	6/10/2020	Bromberg, Brian	0.8	Review IAC diligence report for presentation notes.
28	6/11/2020	Diaz, Matthew	1.6	Perform final review of the IAC reports for the due diligence subcommittee.
28	6/11/2020	Diaz, Matthew	0.6	Review the updated IAC diligence request list.
28	6/11/2020	Kim, Ye Darm	0.4	Review central cost updates for IAC business plan diligence presentation.
28	6/11/2020	Kim, Ye Darm	2.1	Update country-level sales charts re: IAC business plan diligence presentation.
28	6/11/2020	Kurtz, Emma	2.7	Prepare slides for revised IAC business plan presentation re: consolidated and regional sales by product category to evaluate business plan projections.
28	6/11/2020	Kurtz, Emma	1.2	Analyze revised business plan projections by entity to prepare bridge analysis from 2019 to 2024.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
28	6/11/2020	Bromberg, Brian	0.5	Present to diligence committee on IAC diligence report.
28	6/11/2020	Bromberg, Brian	0.7	Review proposed UCC letter to IAC management and provide comments.
28	6/11/2020	Bromberg, Brian	1.4	Review updated IAC P&L variance analysis.
28	6/12/2020	Kim, Ye Darm	0.8	Review direct / central cost figures in updated plan numbers.
28	6/12/2020	Kurtz, Emma	2.4	Prepare slides re: analysis of central costs in revised IAC business plan.
28	6/12/2020	Kurtz, Emma	1.3	Prepare analysis of central costs within the revised IAC business plan.
28	6/12/2020	Bromberg, Brian	0.3	Provide comments on UCC letter to IAC management.
28	6/12/2020	Bromberg, Brian	0.5	Participate in call with NCSG re: IACs.
28	6/13/2020	Bromberg, Brian	0.7	Send IAC diligence questions to Huron.
28	6/13/2020	Bromberg, Brian	2.5	Review newly provided IAC diligence provided and prepare summary for team.
28	6/14/2020	Kurtz, Emma	2.2	Prepare analysis of Southeast Asia sales by product, as a region and by individual country, in preparation for call with head of Southeast Asia.
28	6/14/2020	Bromberg, Brian	0.5	Review diligence questions for southeast Asia IAC manager.
28	6/15/2020	Kim, Ye Darm	1.8	Review product P&L model provided by Huron for sales trends by country/entity.
28	6/15/2020	Kim, Ye Darm	1.4	Review latest IAC P&L model provided by Huron.
28	6/15/2020	Kurtz, Emma	1.3	Prepare analysis of Latin America sales by product to prepare for diligence call with regional manager.
28	6/15/2020	Kurtz, Emma	2.2	Prepare analysis of product-level P&L received from the Company to evaluate sales and costs by product by entity.
28	6/15/2020	Kurtz, Emma	0.5	Review revised budget received from the Company incorporating product-level information.
28	6/15/2020	Bromberg, Brian	3.2	Review product level backup files for IACs.
28	6/15/2020	Bromberg, Brian	2.8	Review newly provided P&L for IACs.
28	6/16/2020	Kurtz, Emma	1.4	Update sales by product analysis by country for Southeast Asia to reflect revised P&L in preparation for call with country manager.
28	6/16/2020	Kurtz, Emma	0.6	Prepare diligence questions in preparation for call with Southeast Asia country manager.
28	6/16/2020	Kurtz, Emma	0.9	Prepare revisions to analysis of revised product-level P&L to incorporate internal comments.
28	6/16/2020	Kurtz, Emma	1.1	Prepare revisions to Southeast Asia slides to include revised sales by product information and country-level P&Ls.
28	6/16/2020	Kurtz, Emma	1.8	Prepare analysis of product sales and costs build-up by entity to evaluate revised budget information.
28	6/16/2020	Bromberg, Brian	0.8	Review Southeast Asia IAC financials ahead of call with country manager.
28	6/16/2020	Bromberg, Brian	0.8	Continue to review analysis on newly provided product level backup.
28	6/16/2020	Bromberg, Brian	2.3	Review analysis on newly provided product level backup.
28	6/17/2020	Diaz, Matthew	1.3	Review the updated IAC business plan diligence materials.
28	6/17/2020	Kim, Ye Darm	2.8	Continue updating IAC diligence deck for qualitative sales trends information.
28	6/17/2020	Kim, Ye Darm	2.6	Continue updating IAC diligence deck for qualitative information on sales trends.
28	6/17/2020	Kim, Ye Darm	1.3	Update IAC diligence deck for qualitative sales trend information.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
28	6/17/2020	Kurtz, Emma	0.8	Prepare additional questions for the Southeast Asia region manager to account for commentary previously received in response to diligence questions.
28	6/17/2020	Kurtz, Emma	0.4	Prepare revisions to analysis of revised product-level P&L to incorporate internal comments.
28	6/17/2020	Bromberg, Brian	0.8	Review diligenc questions for southeast Asia IAC manager.
28	6/17/2020	Bromberg, Brian	1.2	Review Southeast Asia IAC diligence responses ahead of call with country manager.
28	6/17/2020	Bromberg, Brian	1.6	Review IAC product analysis model and provide revisions.
28	6/18/2020	Kurtz, Emma	1.8	Update IAC April business plan review presentation to reflect revised product-level P&L received from the Company.
28	6/19/2020	Diaz, Matthew	1.7	Review responses to the IAC diligence questions and materials provided.
28	6/19/2020	Kim, Ye Darm	1.2	Review responses to China IAC diligence questions from Huron.
28	6/19/2020	Kurtz, Emma	1.8	Prepare revisions to Latin America slides to reflect latest analysis re: product-level P&L in preparation for call with regional manager.
28	6/19/2020	Bromberg, Brian	0.8	Review E&Y vendor due diligence report to compare with diligence responses.
28	6/19/2020	Bromberg, Brian	0.7	Review responses on diligence questions for China IAC.
28	6/21/2020	Bromberg, Brian	0.5	Review E&Y consumer health vendor due diligence report to compare with diligence responses.
28	6/22/2020	Diaz, Matthew	0.6	Review diligence questions for E&Y re: vendor due diligence.
28	6/22/2020	Kim, Ye Darm	0.4	Review diligence topics for call with EY.
28	6/23/2020	Kim, Ye Darm	1.2	Prepare summary of EY call for distribution to internal team.
28	6/23/2020	Kim, Ye Darm	1.1	Participate in diligence call with EY re: IAC VDD report.
28	6/23/2020	Kurtz, Emma	0.6	Participate in call with E&Y to discuss progress on VDD report.
28	6/23/2020	Bromberg, Brian	0.3	Prepare summary of diligence call with E&Y re: IAC vendor due diligence status.
28	6/23/2020	Bromberg, Brian	0.5	Participate in call with E&Y re: IAC vendor due diligence status.
28	6/24/2020	Diaz, Matthew	1.8	Participate in a call with IAC CFO to review the IAC performance and diligence.
28	6/24/2020	Kim, Ye Darm	0.5	Review question list for LatAm regional manager in preparation of call the following day.
28	6/24/2020	Kim, Ye Darm	2.0	Participate in call with IAC global CFO re: business plan diligence.
28	6/24/2020	Kim, Ye Darm	1.2	Review LatAm product slides in preparation for call the following day.
28	6/24/2020	Kim, Ye Darm	1.1	Review materials shared for the CFO diligence call.
28	6/24/2020	Kim, Ye Darm	0.8	Review question list and diligence items to prepare for CFO call.
28	6/24/2020	Kurtz, Emma	1.7	Participate in call with Arnaud Breabout re: IAC 2020 business plan and YTD 2020 performance.
28	6/24/2020	Kurtz, Emma	0.9	Prepare diligence questions for call with Latin America regional manager.
28	6/24/2020	Bromberg, Brian	0.8	Review CFO provided diligence responses and materials.
28	6/24/2020	Bromberg, Brian	2.0	Participate in call with global CFO re: IAC diligence.
28	6/24/2020	Bromberg, Brian	0.7	Review LatAm diligence questions to prepare for diligence call.
28	6/24/2020	Bromberg, Brian	1.2	Review financial information to prepare for call with LatAm IAC.
28	6/24/2020	Bromberg, Brian	1.2	Review product P&L backup to prepare for LatAM IAC diligence call.
28	6/25/2020	Diaz, Matthew	1.4	Review the updated LATAM diligence requests and responses.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
28	6/25/2020	Kim, Ye Darm	0.9	Prepare summary of LatAm diligence call for distribution to internal team.
28	6/25/2020	Kim, Ye Darm	1.1	Participate in meeting with LatAm regional manager re: business plan diligence.
28	6/25/2020	Kurtz, Emma	1.1	Participate in diligence call with Latin America regional manager re: revised business plan.
28	6/25/2020	Bromberg, Brian	1.0	Participate in call with LatAm IAC subregional manager.
28	6/25/2020	Bromberg, Brian	1.1	Review provided P&L information for Southeast Asia IAC.
28	6/25/2020	Bromberg, Brian	1.2	Review Project Malta model analysis and provide revisions.
28	6/25/2020	Bromberg, Brian	0.5	Review diligence questions for southeast Asia IAC manager.
28	6/25/2020	Bromberg, Brian	1.0	Prepare summary of IAC CFO call for internal distribution.
28	6/26/2020	Diaz, Matthew	1.1	Perform detailed review of the updated IAC due diligence requests and responses.
28	6/26/2020	Kim, Ye Darm	1.3	Review presentations from Huron re: SEA and LatAm regions.
28	6/26/2020	Kim, Ye Darm	1.1	Participate in diligence call with SEA regional manager re: business plan diligence.
28	6/26/2020	Kim, Ye Darm	0.8	Review draft questions for meetings with Europe, LAM, and TechOps.
28	6/26/2020	Kim, Ye Darm	0.9	Prepare summary of call with SEA manager for internal distribution.
28	6/26/2020	Kurtz, Emma	0.8	Prepare diligence questions in preparation for call with Alberto Martinez.
28	6/26/2020	Kurtz, Emma	1.0	Participate in diligence call with Southeast Asia regional manager to discuss the revised business plan.
28	6/26/2020	Kurtz, Emma	0.6	Prepare questions for the call with Birgit Kudlek re: TechOps revised business plan and YTD performance.
28	6/26/2020	Kurtz, Emma	0.9	Prepare diligence questions for discussion with Raman Singh.
28	6/26/2020	Bromberg, Brian	1.0	Participate in diligence call with Southeast Asia IAC country manager.
28	6/26/2020	Bromberg, Brian	1.0	Review diligence materials to prepare for Southeast Asia IAC country manager call.
28	6/26/2020	Bromberg, Brian	1.4	Review provided materials to build question list for future management calls.
28	6/27/2020	Bromberg, Brian	2.1	Create topic list for call with Europe IAC CEO.
28	6/29/2020	Suric, Emil	1.5	Review of due diligence documents pertaining to new BD opportunity and call with Purdue Management to discuss opportunity.
28	6/29/2020	Diaz, Matthew	1.1	Review diligence question lists for calls on LATAM IACs and IAC head of tech ops.
28	6/29/2020	Kim, Ye Darm	0.6	Review updated question list re: LAM and TechOps.
28	6/29/2020	Bromberg, Brian	1.8	Review IAC financial information provided in dataroom to prepare for future management diligence calls.
28	6/29/2020	Bromberg, Brian	1.3	Create diligence question list for LatAm CEO.
28	6/29/2020	Bromberg, Brian	0.4	Review diligence question list for LatAm CEO.
28	6/29/2020	Bromberg, Brian	0.8	Review diligence question list for IAC head of technical operations.
28	6/29/2020	Bromberg, Brian	1.2	Create question list for IAC head of technical operations.
28	6/29/2020	Bromberg, Brian	0.3	Revise question lists for calls with IAC management.
28	6/30/2020	Diaz, Matthew	0.8	Review the updated IAC due diligence request list.
28	6/30/2020	Diaz, Matthew	0.7	Review the IAC due diligence update presentation for the committee.
28	6/30/2020	Kim, Ye Darm	1.0	Participate in call with EUR manager re: IAC diligence.
28	6/30/2020	Kim, Ye Darm	2.1	Prepare summary outline of IAC diligence updates for Committee re: EY VDD, IAC YTD financials, IAC budget to actual variances.

EXHIBIT C
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Task Category	Date	Professional	Hours	Activity
28	6/30/2020	Kurtz, Emma	0.4	Prepare revisions to Steve Jamieson question list to incorporate internal comments.
28	6/30/2020	Kurtz, Emma	1.1	Participate in diligence call with Alberto Martinez, the Europe regional manager, to discuss the revised business plan.
28	6/30/2020	Kurtz, Emma	1.2	Review outstanding questions for Steve Jamieson to prepare revised diligence question list.
28	6/30/2020	Bromberg, Brian	1.5	Review IAC product analysis model and provide revisions.
28	6/30/2020	Bromberg, Brian	1.3	Prepare update on ongoing IAC diligence for Committee.
28	6/30/2020	Bromberg, Brian	0.5	Prepare summary and review outstanding diligence items re: IAC CEO diligence Call.
28	6/30/2020	Bromberg, Brian	1.0	Participate in call with IAC Europe CEO.
28	6/30/2020	Bromberg, Brian	0.5	Review diligence materials and question lists to prepare for call with Europe CEO.
28	6/30/2020	Bromberg, Brian	1.7	Review updated diligence question list for IAC accountant.
28 Total			183.9	
Grand Total			498.4	

EXHIBIT D**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF EXPENSES****FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020**

Expense Type	Amount¹
Working Meals	\$ 80.00
Other	\$ 16.90
Grand Total	\$ 96.90

1. Working Meals have been voluntarily reduced to the lesser of \$20 per person or the actual amount charged.

EXHIBIT E
PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
EXPENSE DETAIL
FOR THE PERIOD JUNE 1, 2020 TO JUNE 30, 2020

Date	Professional	Expense Type	Expense Detail	Amount
2/24/2020	Kim, Ye Darm	Working Meals	Working meal while working late in the office.	\$ 20.00
2/24/2020	Bromberg, Brian	Working Meals	Working meal while working late in the office.	20.00
2/25/2020	Bromberg, Brian	Working Meals	Working meal while working late in the office.	20.00
2/26/2020	Bromberg, Brian	Working Meals	Working meal while working late in the office.	20.00
Working Meals Total				\$ 80.00
6/1/2020	Harsha, Adam	Other	Access to Pennsylvania corporate records of Debtor-affiliated entities for the HRT motion.	\$ 6.00
6/30/2020	Butterfield, Linda	Other	Access to Lexis Nexis for research regarding the HRT motion.	10.90
Other Total				\$ 16.90
Grand Total				\$ 96.90